SCHEMBL1930005

SCHEMBL1930005

Cc1csc(NC(N)=O)c1C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHB4 P54760 1/20 0.40
MAPK10 P53779 5/20 0.40
MAPK8 P45983 4/20 0.40
MAPK9 P45984 4/20 0.40
MAPT P10636 3/20 0.40
MAPK1 P28482 1/20 0.37
IKBKB O14920 2/20 0.37
ALDH1A1 P00352 3/20 0.36
RAB9A P51151 3/20 0.36
HPGD P15428 2/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
PTK2 Q05397 1/20 0.35
AIP O00170 1/20 0.35
SGTA O43765 1/20 0.35
TOMM70 O94826 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16246364 0.87 PTK2 (0.49) EPHB4MAPK10MAPK8MAPK9MAPT
SCHEMBL26295499 0.86 EPHB4 (0.39) EPHB4MAPK10MAPK8MAPK9MAPT
SCHEMBL14585671 0.83 ADRA2A (0.36) EPHB4MAPK10MAPK8MAPK9MAPT
SCHEMBL15965535 0.82 ANO1 (0.38) EPHB4MAPK10MAPK8MAPK9MAPT
SCHEMBL20014923 0.80 MAPK1 (0.58) MAPK10MAPK8MAPK9MAPTMAPK1
SCHEMBL560978 0.79 IKBKB (0.35) EPHB4MAPK8MAPTMAPK1IKBKB
SCHEMBL12204339 0.79 EPHB4 (0.36) EPHB4MAPK10MAPK8MAPK9MAPT
SCHEMBL24322190 0.79 MELK (0.40) EPHB4MAPK10MAPK8MAPK9MAPT
SCHEMBL941528 0.78 ALDH1A1 (0.47) EPHB4MAPK10MAPK8MAPK9MAPT
SCHEMBL7002116 0.74 FLT3 (0.46) MAPTMAPK1ALDH1A1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110152234-A1 Novel Compounds ASTRAZENECA AB (SE) 2011-06-23 US disclosed
US-7956084-B2 Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 ASTRAZENECA AB (SE) 2011-06-07 US disclosed
EP-1421074-B1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2010-09-29 EP disclosed
US-20070015819-A1 Novel compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2007-01-18 US disclosed
US-7125896-B2 Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 ASTRAZENECA AB (SE) 2006-10-24 US disclosed
US-20040242573-A1 Novel compounds ASTRAZENECA AB (SE) 2004-12-02 US disclosed
EP-1421074-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2004-05-26 EP disclosed
WO-2003010158-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015819-A1 Novel compounds CNR1, ABCG2, CNR2 EPHB4 2733/4885MAPK10 3958/4885MAPK8 4539/4885
US-20040242573-A1 Novel compounds SULT1E1, TPMT, UGT1A1 EPHB4 3230/4885MAPK10 3787/4885MAPK8 4468/4885
US-20110152234-A1 Novel Compounds CNR1, ABCG2, CNR2 EPHB4 2733/4885MAPK10 3958/4885MAPK8 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.